CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants
3D Printed Breast implants consisting of 200cc in volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin® printer to...
Clinical Trial
The Caris Precision Oncology Alliance Welcomes The University of Hawai’i Cancer Center
Caris expands its extensive network of leading cancer institutions committed to improving patient outcomes through innovations in precision medicine by...
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
MIAMI, FL / ACCESSWIRE / August 19, 2024 / MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) "MIRA" or the "Company"), a leading pre-clinical-stage...
MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
Three months post cessation of an 8-week course of microdosing treatment, the antidepressant response is sustained with a 62.8% reduction...
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Following recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026Ongoing Phase...
Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders
COPENHAGEN, Denmark, August 17, 2024 – Bavarian Nordic A/S (OMX: BAVA) provides an update on plans for securing supply of...
Audax Private Equity to Acquire Avantor’s Clinical Services Business
SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Audax Private Equity (“Audax”) announced today it has entered into a definitive agreement to acquire the...
CodaMetrix’s AI Platform Now Available in Epic Toolbox to Transform $20B Medical Coding Sector
CodaMetrix’s AI platform, developed with and used by 20 top U.S. health systems, efficiently and accurately transforms patient records into...
Results From European Randomized Controlled Study Using XVIVO’s Heart Technology Published in The Lancet
GOTHENBURG, SWEDEN / ACCESSWIRE / August 16, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, the results of the European randomized...
Genmab Announces Changes to its Executive Committee
Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology OfficerBrad Bailey appointed...
Safety Shot Releases Second Quarter 2024 Results and Corporate Highlights
- Q2 Revenues Increased 40%- Q2 Operating Expenses Decreased 17.7%- Recent Clinical Trial Confirms Dramatic Reduction of Blood Alcohol Content-...
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company...
Therma Bright’s AI-Powered Digital Cough Technology Being Considered as Partner Technology in New Chronic Cough Drug Clinical Trial
Toronto, Ontario--(Newsfile Corp. - August 16, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a...
4G Clinical Announces Appointment of Life Science Service and Tech Leader Dr. Ronan Brown as New Chief Operating Officer
Brown brings years of industry expertise to oversee and maximize 4G Clinical's operational efficiency and excellence. WELLESLEY, Mass., Aug. 15,...
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
Potentially pivotal GBM study evaluating lead program, Berubicin, enrollment completed; Topline data expected in the first half of 2025Recent strategic...
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's...
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBMPart B expected...
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company...
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to...